Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma
NCT01180959Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2011
- Primary completion
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, bevacizumab in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2011; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01180959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01180959.